Markets:

Overview

News

Currencies

International

Treasuries

ResMed Inc. Common Stock (NY:RMD)

229.46 +0.59 (+0.26%)

Streaming Delayed Price Updated: 3:05 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Where ResMed Stands With Analysts ↗

October 28, 2022

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Via Benzinga

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023

October 27, 2022

From ResMed Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022 ↗

October 20, 2022

Upgrades

Via Benzinga

Competitor Recall Continues To Show Opportunities For ResMed ↗

August 12, 2022

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

Analyst Ratings for ResMed ↗

June 06, 2022

Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:

Via Benzinga

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract ↗

April 29, 2022

Via Benzinga

What 5 Analyst Ratings Have To Say About ResMed ↗

April 06, 2022

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Via Benzinga

ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022

October 13, 2022

From ResMed Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022 ↗

October 12, 2022

Upgrades

Via Benzinga

Silk Road Medical Stock Scores Relative Strength Rating Upgrade ↗

September 28, 2022

Silk Road Medical sees its Relative Strength Rating reach the elite 90-plus level.

Via Investor's Business Daily

Hopeful Golden Cross Forms On ResMed's Chart ↗

September 22, 2022

If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE:RMD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Via Benzinga

Tuesday Is Your Last Chance To Buy ResMed Before The Dividend Payout ↗

August 12, 2022

Tuesday marks the last chance for investors to receive the next dividend payout from ResMed (NYSE:RMD).

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $3,400 Today ↗

August 03, 2022

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.43% on an annualized basis producing an average annual return of 19.33%. Currently, ResMed has a market capitalization of...

Via Benzinga

How Is The Market Feeling About ResMed? ↗

July 25, 2022

ResMed's (NYSE:RMD) short percent of float has fallen 6.8% since its last report. The company recently reported that it has 1.39 million shares sold short, which is 0.96% of all...

Via Benzinga

Semiconductor Shortages - See How ResMed Is Tackling ↗

July 22, 2022

ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022 ↗

August 12, 2022

Via Benzinga

Here's How Much $1000 Invested In ResMed 10 Years Ago Would Be Worth Today ↗

July 18, 2022

ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 10.69% on an annualized basis producing an average annual return of 21.91%. Currently, ResMed has a market capitalization of...

Via Benzinga

Peering Into ResMed's Recent Short Interest ↗

July 08, 2022

ResMed's (NYSE:RMD) short percent of float has risen 14.44% since its last report. The company recently reported that it has 1.50 million shares sold short, which is 1.03% of all...

Via Benzinga

7 Growth Stocks to Buy in July 2022 ↗

July 04, 2022

The severe macroeconomic climate has led investors toward defensive plays, creating buy opportunities in the following growth stocks.

Via InvestorPlace

Analyzing ResMed's Short Interest ↗

June 22, 2022

ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all...

Via Benzinga

Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years ↗

June 15, 2022

ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81...

Via Benzinga

ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How ↗

June 14, 2022

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 06, 2022

Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.

Via Benzinga

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street ↗

June 06, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May.

Via Benzinga

If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today ↗

June 02, 2022

ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of...

Via Benzinga

ResMed Earnings Perspective: Return On Invested Capital ↗

May 03, 2022

Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.

Via Benzinga

What 3 Analyst Ratings Have To Say About ResMed ↗

April 29, 2022

Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's...

Via Benzinga

Earnings Outlook For ResMed ↗

April 27, 2022

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.